These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26252723)

  • 1. The Case of Pharmacological Neuroenhancement: Medical, Judicial and Ethical Aspects from a German Perspective.
    Franke AG; Northoff R; Hildt E
    Pharmacopsychiatry; 2015 Nov; 48(7):256-64. PubMed ID: 26252723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects.
    Franke AG; Bagusat C; Rust S; Engel A; Lieb K
    Eur Arch Psychiatry Clin Neurosci; 2014 Nov; 264 Suppl 1():S83-90. PubMed ID: 25214391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement.
    Franke AG; Lieb K; Hildt E
    PLoS One; 2012; 7(6):e40047. PubMed ID: 22768218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulant abuse as a coping strategy-Forensic and criminal consequences of stimulant abuse for neuroenhancement.
    Dominik P; Waßmer MP; Soyka M; Franke AG
    Front Public Health; 2022; 10():1028654. PubMed ID: 36388290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological neuroenhancement and brain doping : Chances and risks].
    Franke AG; Lieb K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Aug; 53(8):853-9. PubMed ID: 20700786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Characteristics of university students using stimulants for cognitive enhancement: a pilot study].
    Franke AG; Schwarze CE; Christmann M; Bonertz C; Hildt E; Lieb K
    Psychiatr Prax; 2012 May; 39(4):174-80. PubMed ID: 22318482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Doping for the brain].
    Iglseder B
    Z Gerontol Geriatr; 2018 Feb; 51(2):143-148. PubMed ID: 29209802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Just "Like Coffee" or Neuroenhancement by Stimulants?
    Franke AG; Koller G; Krause D; Proebstl L; Kamp F; Pogarell O; Jebrini T; Manz K; Chrobok AI; Soyka M
    Front Public Health; 2021; 9():640154. PubMed ID: 34164365
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacological cognitive enhancement from a perspective of misuse and addiction].
    Franke AG; Soyka M
    Fortschr Neurol Psychiatr; 2015 Feb; 83(2):83-90. PubMed ID: 25723772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric Comorbidity and Stress in Medical Students Using Neuroenhancers.
    Jebrini T; Manz K; Koller G; Krause D; Soyka M; Franke AG
    Front Psychiatry; 2021; 12():771126. PubMed ID: 34975573
    [No Abstract]   [Full Text] [Related]  

  • 11. [Neuroenhancement in healthy subject? A French case study].
    Micoulaud-Franchi JA; Vion-Dury J; Lancon C
    Therapie; 2012; 67(3):213-21. PubMed ID: 22874487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tracking the cognitive pharmacodynamics of psychoactive substances with combinations of behavioral and neurophysiological measures.
    Gevins A; Smith ME; McEvoy LK
    Neuropsychopharmacology; 2002 Jan; 26(1):27-39. PubMed ID: 11751030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence Estimates for Pharmacological Neuroenhancement in Austrian University Students: Its Relation to Health-Related Risk Attitude and the Framing Effect of Caffeine Tablets.
    Dietz P; Iberl B; Schuett E; van Poppel M; Ulrich R; Sattler MC
    Front Pharmacol; 2018; 9():494. PubMed ID: 29946254
    [No Abstract]   [Full Text] [Related]  

  • 14. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine.
    Phillips JA; Holland MG; Baldwin DD; Gifford-Meuleveld L; Mueller KL; Perkison B; Upfal M; Dreger M
    Workplace Health Saf; 2015 Apr; 63(4):139-64. PubMed ID: 25862727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive neuroenhancement: false assumptions in the ethical debate.
    Heinz A; Kipke R; Heimann H; Wiesing U
    J Med Ethics; 2012 Jun; 38(6):372-5. PubMed ID: 22228818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Off-label use of psychotropic medications in pediatric wards: a prospective study].
    Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O
    Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A primer on caffeine pharmacology and its drug interactions in clinical psychopharmacology.
    Donovan JL; DeVane CL
    Psychopharmacol Bull; 2001; 35(3):30-48. PubMed ID: 12397877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Neuroenhancement: Current Aspects of Categorization, Epidemiology, Pharmacology, Drug Development, Ethics, and Future Perspectives.
    Daubner J; Arshaad MI; Henseler C; Hescheler J; Ehninger D; Broich K; Rawashdeh O; Papazoglou A; Weiergräber M
    Neural Plast; 2021; 2021():8823383. PubMed ID: 33519929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroenhancement: status quo and perspectives.
    Normann C; Berger M
    Eur Arch Psychiatry Clin Neurosci; 2008 Nov; 258 Suppl 5():110-4. PubMed ID: 18985306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurocognitive enhancement or impairment? A systematic meta-analysis of prescription stimulant effects on processing speed, decision-making, planning, and cognitive perseveration.
    Marraccini ME; Weyandt LL; Rossi JS; Gudmundsdottir BG
    Exp Clin Psychopharmacol; 2016 Aug; 24(4):269-84. PubMed ID: 27454675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.